Pluristem Therapeutics Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (41)

Latest Posts

About This Stock More About This Stock
3 Penny Stocks Insiders Are Buying
Article By: Benzinga
Tuesday, February 15, 2022 9:40 AM EDT
Although Eurozone economy grew 0.3% on quarter during the last three months of 2021, in-line with flash estimates, there were a few notable insider trades.
In this article: PSTI, IMRA, SNSE
Read
The Bright Future Of Pluristem Therapeutics
Article By: I Know First Research
Monday, February 22, 2016 7:21 AM EDT
On January 14th, PSTI got FDA clearance to begin a phase 1 trial on PLX-R18 cells for the treating incomplete hematopoietic recovery following hematopoietic cell transplantation.
In this article: PSTI
Read
Monday Morning’s Pre-Market Insights: YOKU, QCOM, TEVA, PSTI
Article By: TipRanks
Monday, July 27, 2015 9:12 AM EDT
Teva Pharmaceutical Industries Ltd. shares spiked more than 15% in pre-market trading to $71.36 after the company announced plans to acquire Allergan Generics for $40.5 billion.
In this article: YOKU, QCOM, TEVA, PSTI Also: AGN
Read
Monday Pre-Market Insights: PSTI, JUNO, OSUR, SGYP
Article By: TipRanks
Monday, May 18, 2015 8:59 AM EDT
Monday Pre-Market Insights: PSTI, JUNO, OSUR, SGYP.
In this article: PSTI, JUNO, OSUR, SGYP
Read
AGIO Reports Phase 1/2 Clinical Trial Of AG-221; PSTI Advances Its Second Major Cell Therapy Product Line
Article By: BioMedReports
Wednesday, October 22, 2014 3:24 AM EDT
Agios Pharmaceuticals announced the initiation of a Phase 1/2 multicenter study of AG-221 in patients with advanced solid tumors. Pluristem Therapeutics announced it has completed development of its second major product line.
In this article: PSTI, AGIO
Read

Latest Tweets for $PSTI

No tweets yet!

PARTNER HEADLINES